open access

Vol 81, No 10 (2010)
ARTICLES
Get Citation

Androgen and 17-hydroxyprogesterone concentrations in blood serum versus menstrual patterns in women with polycystic ovary syndrome (PCOS)

Ewa Rudnicka, Michał Kunicki, Stanisław Radowicki
Ginekol Pol 2010;81(10).

open access

Vol 81, No 10 (2010)
ARTICLES

Abstract

Abstract The aim of the study: to evaluate correlation between androgen and 17-hydroksyprogetserone concentrations in blood serum and menstrual patterns of women with polycystic ovary syndrome. Material and methods: 227 patients with polycystic ovarian syndrome (PCOS), aged 18 to 35 years, hospitalized at the Department of Gynecological Endocrinology. All patients with PCOS presented clinical and biochemical evidence of hiperandrogenism with oligoovulation and/or ultrasonographic appearance of polycystic ovaries. PCOS was diagnosed according to the Rotterdam Criteria after excluding reasons such as: congenital adrenal hiperplasia, adrenal and ovarian tumors, hiperprolactinemia and hypo- hiperthyreosis. The following hormone concentrations were measured in each patient: total testosterone (TT), androstendione (A), dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxyprogesterone (17-OHP). The patients were divided into 4 groups: I – eumenorrhoeic (n=66), II – polymenorrhoeic (n=32), III – oligomenorrhoeic (n=93), IV – with secondary amenorrhea (n=36). The control group consisted of 40 patients with normal regular menstrual cycles and no clinical/biochemical sings of hiperandrogenism. Statistical analysis was performed using one-way Anova and NIR test. P<0,05 were considered to be statistically significant. Results: The mean TT concentrations were as follows: Group I - 0.91± 0.56 ng/ml, II -0.91±0.22, III – 0.91±0.48, IV – 1.66±1.78ng/ml; Androstendione: I – 3.34±1.32, II – 2.77±0.75ng/ml, III – 3.28±1.00ng/ml, IV – 4.29±2.18ng/ml, 17-OHP: I – 1.08±1.61ng/ml, II – 0.89±0.62ng/ml, III – 0.94±0.37ng/ml; IV – 1.68±1.28ng/ml and DHEAS: I – 5.69±2.49μmol/l, II – 6.11±3.11μmol/l, III – 6.04±3.00μmol/l, IV – 6.12±3.25μmol/l respectively. The hormone concentrations in the control group were as follows: TT – 0.58±0.35ng/ml, A – 2.33±0.52ng/ml, 17-OHP – 0.67±0.30ng/ml, DHEAS – 5.24±2.33μmol/l. We found significantly higher TT, A, 17-OHP concentrations in all PCOS subgroups than in the healthy subjects (p<0.05). The PCOS group analysis revealed that all the mentioned hormone concentrations were significantly higher in women with secondary amenorrhea (group IV) than in the remaining 3 groups (p<0.05). We found no significant difference in DHEAS concentrations between the study and the control group. Conclusions: Higher total testosterone, androstendione and 17-hydroksyprogesterone concentrations, longer menstrual cycles in women with PCOS.

Abstract

Abstract The aim of the study: to evaluate correlation between androgen and 17-hydroksyprogetserone concentrations in blood serum and menstrual patterns of women with polycystic ovary syndrome. Material and methods: 227 patients with polycystic ovarian syndrome (PCOS), aged 18 to 35 years, hospitalized at the Department of Gynecological Endocrinology. All patients with PCOS presented clinical and biochemical evidence of hiperandrogenism with oligoovulation and/or ultrasonographic appearance of polycystic ovaries. PCOS was diagnosed according to the Rotterdam Criteria after excluding reasons such as: congenital adrenal hiperplasia, adrenal and ovarian tumors, hiperprolactinemia and hypo- hiperthyreosis. The following hormone concentrations were measured in each patient: total testosterone (TT), androstendione (A), dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxyprogesterone (17-OHP). The patients were divided into 4 groups: I – eumenorrhoeic (n=66), II – polymenorrhoeic (n=32), III – oligomenorrhoeic (n=93), IV – with secondary amenorrhea (n=36). The control group consisted of 40 patients with normal regular menstrual cycles and no clinical/biochemical sings of hiperandrogenism. Statistical analysis was performed using one-way Anova and NIR test. P<0,05 were considered to be statistically significant. Results: The mean TT concentrations were as follows: Group I - 0.91± 0.56 ng/ml, II -0.91±0.22, III – 0.91±0.48, IV – 1.66±1.78ng/ml; Androstendione: I – 3.34±1.32, II – 2.77±0.75ng/ml, III – 3.28±1.00ng/ml, IV – 4.29±2.18ng/ml, 17-OHP: I – 1.08±1.61ng/ml, II – 0.89±0.62ng/ml, III – 0.94±0.37ng/ml; IV – 1.68±1.28ng/ml and DHEAS: I – 5.69±2.49μmol/l, II – 6.11±3.11μmol/l, III – 6.04±3.00μmol/l, IV – 6.12±3.25μmol/l respectively. The hormone concentrations in the control group were as follows: TT – 0.58±0.35ng/ml, A – 2.33±0.52ng/ml, 17-OHP – 0.67±0.30ng/ml, DHEAS – 5.24±2.33μmol/l. We found significantly higher TT, A, 17-OHP concentrations in all PCOS subgroups than in the healthy subjects (p<0.05). The PCOS group analysis revealed that all the mentioned hormone concentrations were significantly higher in women with secondary amenorrhea (group IV) than in the remaining 3 groups (p<0.05). We found no significant difference in DHEAS concentrations between the study and the control group. Conclusions: Higher total testosterone, androstendione and 17-hydroksyprogesterone concentrations, longer menstrual cycles in women with PCOS.
Get Citation

Keywords

androgeny, polycystic ovarian syndrome, androgens, Menstrual disturbances

About this article
Title

Androgen and 17-hydroxyprogesterone concentrations in blood serum versus menstrual patterns in women with polycystic ovary syndrome (PCOS)

Journal

Ginekologia Polska

Issue

Vol 81, No 10 (2010)

Bibliographic record

Ginekol Pol 2010;81(10).

Keywords

androgeny
polycystic ovarian syndrome
androgens
Menstrual disturbances

Authors

Ewa Rudnicka
Michał Kunicki
Stanisław Radowicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl